Intranasal immunotherapy with M2 macrophage soluble factors in post-COVID hyposmia: A pilot study.

MLA

Shevela, E.Ya, et al. “Intranasal Immunotherapy with M2 Macrophage Soluble Factors in Post-COVID Hyposmia: A Pilot Study.” International Immunopharmacology, vol. 126, Jan. 2024, p. 111260. EBSCOhost, https://doi.org/10.1016/j.intimp.2023.111260.

APA

Shevela, E. Y., Davydova, M. N., Meledina, I. V., Bogachev, S. S., Ostanin, A. A., Kozlov, V. A., & Chernykh, E. R. (2024). Intranasal immunotherapy with M2 macrophage soluble factors in post-COVID hyposmia: A pilot study. International Immunopharmacology, 126, 111260. https://doi.org/10.1016/j.intimp.2023.111260

Chicago

Shevela, E Ya, M N Davydova, I V Meledina, S S Bogachev, A A Ostanin, V A Kozlov, and E R Chernykh. 2024. “Intranasal Immunotherapy with M2 Macrophage Soluble Factors in Post-COVID Hyposmia: A Pilot Study.” International Immunopharmacology 126 (January): 111260. doi:10.1016/j.intimp.2023.111260.